Recent research highlights the dysfunction of the protein C pathway in antiphospholipid syndrome, suggesting potential new therapeutic avenues. This study may pave the way for innovative treatments targeting this pathway.

A study involving 351 patients reveals that immune thrombocytopenia is rare among those with antiphospholipid syndrome who do not have systemic lupus erythematosus. This finding may influence clinical approaches to managing these patients.

A NIH-funded clinical trial demonstrates that a symptom-based approach effectively treats opioid withdrawal in newborns with minimal drug exposure, potentially reducing hospital stay durations. This innovative strategy could reshape care protocols for affected infants.

A 47-year-old woman in Germany was cured of three severe autoimmune diseases—autoimmune hemolytic anemia, immune thrombocytopenia, and antiphospholipid syndrome—using CAR-T cell therapy, traditionally used for blood cancers. This breakthrough highlights the potential of CAR-T therapy beyond oncology, offering new hope for patients with refractory autoimmune conditions.

A recent study published in PubMed evaluates the criterion validity of the EULAR Antiphospholipid Syndrome Disease Activity Score (EAPSDAS). This research aims to enhance the assessment of disease activity in patients with antiphospholipid syndrome.